

STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT

NCT05785897

Status	RECRUITING
Phase	Not Applicable
Sponsor	IGLESIAS Juan Fernando
Enrollment	350 participants

Key Eligibility Criteria

Inclusion (4)

- Age ≥18 years.
- Subjects who have received DAPT consisting of aspirin and any of the commercially available P2Y12 receptor inhibitors (ticagrelor, prasugrel, or clopidogrel) at the time of STEMI diagnosis, or at the very latest at the time of primary PCI.
- Subjects with ≥1 acute infarct artery target vessel with ≥1 coronary artery stenosis in a native coronary artery with diameter from 2.25 to 4.0 mm who underwent successful primary PCI, defined as primary PCI with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation, and final residual stenosis <30% by visual estimation or 20% by quantitative coronary angiography (QCA) [38].
- Subject willing to participate and able to understand, read and sign the informed consent form.

Exclusion (11)

- Known allergy or intolerance to aspirin, ticagrelor, prasugrel, or sirolimus.
- Inability to adhere to DAPT for at least 6 months.
- Patient already on DAPT at index presentation due to recent PCI for chronic coronary syndrome (<6 months) or ACS (<12 months).
- Patient on chronic oral anticoagulation at index presentation.
- Patient with mechanical complication of STEMI.
- ... and 6 more (see full listing online)

Locations (2 total)

Geneva University Hospitals, Geneva, Canton of Geneva, Switzerland
Zurich University Hospital, Zurich, Switzerland